|
|
Normal
Press Release
| December 16, 2003 |
December 16, 2003
Westaim’s iFire Technology produces 34-inch color inorganic EL display
|
| December 4, 2003 |
December 4, 2003
NUCRYST Pharmaceuticals begins first Phase 2 clinical trial of novel dermatology drug
|
| November 4, 2003 |
November 4, 2003
Westaim announces 2003 third quarter results
|
| August 6, 2003 |
August 6, 2003
Westaim announces 2003 second quarter results
|
| July 22, 2003 |
July 22, 2003
Westaim appoints two new directors
|
| May 20, 2003 |
May 20, 2003
Westaim’s iFire Technology demonstrates high-luminance Color-by-Blue™
|
| April 30, 2003 |
April 30, 2003
Westaim announces 2003 first quarter results
|
| April 29, 2003 |
April 29, 2003
Westaim’s iFire Technology increases manufacturing cost advantage
|
| April 25, 2003 |
April 25, 2003
Westaim’s NUCRYST Pharmaceuticals to pursue new eczema drug
|
| March 12, 2003 |
March 12, 2003
NUCRYST Pharmaceuticals announces additional European approvals
|
| February 20, 2003 |
February 20, 2003
Westaim announces 2002 year-end results
|
| January 20, 2003 |
January 20, 2003
Westaim announces initiatives to maximize shareholder value
|
| January 15, 2003 |
January 15, 2003
Westaim appoints Barry M. Heck President & CEO
|
|
|